Anticoagulants

Anticoagulants prevent the formation and propagation of fibrin clots by interrupting the coagulation cascade. This is one of the most exam-heavy pharmacology topics for NEET PG — expect direct questions on mechanism, the monitoring test, the reversal agent, and renal precautions for every drug class below.

Orientation & classification

Anticoagulants do not dissolve an existing clot (that is the job of thrombolytics/fibrinolytics) and do not primarily block platelets (that is antiplatelets). They prevent new fibrin generation and clot extension. They are broadly grouped as parenteral and oral.

Class	Prototype drugs	Route	Onset	Monitoring test
Indirect thrombin/Xa inhibitors (heparins)	UFH, LMWH (enoxaparin), fondaparinux	Parenteral	Immediate	aPTT (UFH); anti-Xa (LMWH/fonda)
Vitamin K antagonist	Warfarin, acenocoumarol	Oral	Slow (days)	INR/PT
Direct oral anticoagulants (DOACs)	Dabigatran; rivaroxaban, apixaban, edoxaban	Oral	Fast (hours)	Usually none
Direct parenteral thrombin inhibitors	Bivalirudin, argatroban	Parenteral	Immediate	aPTT/ACT

High-yield: Heparin acts both in vivo and in vitro; warfarin acts only in vivo (it needs hepatic synthesis of clotting factors to be affected). This single line is a classic one-liner MCQ.

Heparin (unfractionated heparin, UFH)

Mechanism of action

Heparin is a sulphated mucopolysaccharide (glycosaminoglycan) that binds and activates antithrombin III (ATIII), causing a conformational change that accelerates ATIII's inhibition of clotting factors by ~1000-fold. The key targets are factor IIa (thrombin) and factor Xa.

• For UFH to inactivate thrombin (IIa), the heparin chain must be long enough to bind both ATIII and thrombin simultaneously — this requires the 18-saccharide unit ternary complex.
• For inactivation of Xa, only ATIII binding is needed; chain length is not critical.

This length dependence explains the difference between heparin types:

Property	UFH	LMWH (enoxaparin)	Fondaparinux
Molecular weight	~12,000–15,000	~4,000–5,000	~1,700 (synthetic pentasaccharide)
Anti-Xa : anti-IIa ratio	~1:1	~3:1 to 4:1	Pure anti-Xa only
Route	IV / SC	SC	SC
Monitoring	aPTT	Not routine (anti-Xa if needed)	Not needed
Reversal by protamine	Complete	Partial (~60%)	No
Renal clearance	No (RES)	Yes — caution in renal failure	Yes

High-yield: aPTT is the monitoring test for UFH (target ~1.5–2.5× control). LMWH and fondaparinux do not require routine monitoring; when needed (renal failure, obesity, pregnancy) use the anti-factor Xa assay.

Clinical uses

• Acute venous thromboembolism (DVT/PE), acute coronary syndrome, during PCI/cardiac surgery and dialysis, and anticoagulant of choice in pregnancy (heparins do not cross the placenta; warfarin is teratogenic).

Adverse effects

1. Bleeding — the dose-limiting toxicity.
2. Heparin-induced thrombocytopenia (HIT) — immune (Type II), IgG against platelet factor 4 (PF4)–heparin complex, occurring at day 5–14, causing paradoxical thrombosis despite a falling platelet count. More common with UFH than LMWH.
3. Osteoporosis (long-term), hyperkalaemia (aldosterone suppression), alopecia.

High-yield: In HIT, stop all heparin (including LMWH and flushes) and switch to a non-heparin anticoagulant — argatroban, bivalirudin, or fondaparinux. Do not give platelet transfusion and do not start warfarin until platelets recover (risk of venous limb gangrene/skin necrosis).

Reversal

Protamine sulphate — a positively charged protein that binds the negatively charged heparin (1 mg protamine neutralises ~100 units of UFH). Protamine itself can cause hypotension, anaphylaxis, and is only partially effective for LMWH and ineffective for fondaparinux.

Warfarin (vitamin K antagonist)

Mechanism

Warfarin inhibits vitamin K epoxide reductase (VKORC1), blocking regeneration of reduced vitamin K. This impairs γ-carboxylation of the vitamin K–dependent factors II, VII, IX, X and the anticoagulant proteins C and S.

Mnemonic — "1972" → factors II, IX, VII, X are vitamin K dependent. (Also remember Proteins C & S.)

High-yield: Factor VII has the shortest half-life (~6 h) and falls first → PT/INR rises early. Protein C also has a short half-life and falls early, producing a transient procoagulant state in the first 1–3 days → warfarin-induced skin necrosis (worse in protein C deficiency). Therefore always bridge with heparin until INR is therapeutic for ≥2 days.

Onset & pharmacokinetics

• Slow onset (3–5 days) — full antithrombotic effect waits until preformed factors (especially factor II, half-life ~60 h) are cleared.
• Highly plasma-protein bound, metabolised by CYP2C9; the S-enantiomer is ~3–5× more potent and is the one involved in major interactions.
• Crosses the placenta → teratogenic (fetal warfarin syndrome: nasal hypoplasia, stippled epiphyses, CNS defects); avoid especially in the first trimester.

Monitoring

PT expressed as INR. Standard target INR 2.0–3.0 for most indications; 2.5–3.5 for mechanical mitral valves and certain high-risk states.

$$INR = \left(\frac{PT_{patient}}{PT_{control}}\right)^{ISI}$$

Drug & diet interactions (very high yield)

Potentiate warfarin (↑ INR, bleeding): amiodarone, metronidazole, fluconazole/azoles, cotrimoxazole, ciprofloxacin, cimetidine, NSAIDs (also displace + GI bleed). Reduce warfarin effect (↓ INR): rifampicin, phenytoin/carbamazepine/barbiturates, green leafy vegetables (vitamin K), St John's wort.

Mnemonic for enzyme inducers — "CRAP-GPS": Carbamazepine, Rifampicin, Alcohol (chronic), Phenytoin, Griseofulvin, Phenobarbitone, Sulfonylureas/Smoking.

Reversal & overdose management

Stepwise approach by INR and bleeding:

1. High INR, no/minor bleed → hold warfarin ± oral vitamin K (phytomenadione).
2. Serious/major bleed → IV vitamin K + 4-factor Prothrombin Complex Concentrate (PCC) for immediate factor replacement. PCC is preferred over FFP (faster, smaller volume).
3. FFP is used if PCC is unavailable.

High-yield: Vitamin K reverses warfarin but takes hours (needs new factor synthesis); for an immediate effect in life-threatening bleeding give PCC (or FFP). This time-lag distinction is repeatedly tested.

Direct oral anticoagulants (DOACs / NOACs)

A landmark advance: predictable kinetics, fixed dosing, no routine monitoring, fewer food/drug interactions than warfarin.

Drug	Target	Reversal agent	Renal clearance	Key caution
Dabigatran	Direct thrombin (IIa)	Idarucizumab (monoclonal Ab fragment)	~80% renal	Most renally cleared; dyspepsia; removable by dialysis
Rivaroxaban	Direct factor Xa	Andexanet alfa	~33% renal	Take with food (large dose); once daily
Apixaban	Direct factor Xa	Andexanet alfa	~27% renal	Best DOAC in moderate renal impairment
Edoxaban	Direct factor Xa	Andexanet alfa	~50% renal	Avoid if CrCl too high or too low

The "-xabans" inhibit factor Xa; dabigatran (think "thrombi-gatran") inhibits thrombin.

High-yield: Idarucizumab = specific reversal for dabigatran. Andexanet alfa = reversal for the factor Xa inhibitors (rivaroxaban, apixaban). These reversal pairings are among the most frequently asked recent additions.

High-yield: DOACs are contraindicated in patients with mechanical heart valves and in significant renal impairment (especially dabigatran). For mechanical valves and antiphospholipid syndrome, warfarin remains the anticoagulant of choice.

DOAC advantages and limits

• No INR monitoring, rapid onset/offset, fewer interactions → first-line for non-valvular AF and VTE in most guidelines.
• Disadvantages: cost, renal dose adjustment (CrCl-based), avoid in pregnancy, and limited evidence for valvular disease.

Parenteral direct thrombin inhibitors

• Bivalirudin, argatroban, lepirudin/desirudin (hirudin analogues).
• Argatroban (hepatic clearance) and bivalirudin are the agents of choice in HIT and during PCI when heparin is contraindicated.
• Argatroban prolongs the INR — a trap when transitioning to warfarin.

Fondaparinux

Synthetic pentasaccharide, pure indirect factor Xa inhibitor via ATIII. Once-daily SC, no monitoring, no protamine reversal. Useful in HIT prophylaxis and VTE. Renally cleared — avoid in severe renal failure.

Clinical decision flow — choosing an anticoagulant

Acute VTE / ACS, need rapid effect → parenteral heparin (UFH if renal failure or reversibility needed; LMWH otherwise) → transition to oral. Pregnancy → LMWH/UFH (never warfarin, never DOAC). Mechanical valve / APLA syndrome → warfarin (target INR per valve) with heparin bridge. Non-valvular AF, normal renal function → DOAC first-line. HIT → stop heparin → argatroban/bivalirudin/fondaparinux.

Complications & differentials

• Bleeding is the universal class toxicity — intracranial, GI, retroperitoneal. Assess with the appropriate test (aPTT, INR) and reverse per agent.
• Differentiate from antiplatelets (aspirin, clopidogrel, ticagrelor — act on platelet aggregation, monitored clinically) and thrombolytics (alteplase, tenecteplase, streptokinase — dissolve formed clot, used in STEMI/massive PE/stroke).
• Differentiate heparin bleeding (aPTT↑, reverse with protamine) from warfarin bleeding (INR↑, reverse with vitamin K/PCC).

Feature	Heparin	Warfarin
Onset	Immediate	Delayed (days)
Route	Parenteral	Oral
Site of action	In vivo + in vitro	In vivo only
Monitoring	aPTT	PT/INR
Crosses placenta	No (safe)	Yes (teratogenic)
Antidote	Protamine	Vitamin K / PCC
Mechanism	Activates ATIII	Inhibits VKORC1

Recently asked / exam angle

• Reversal-agent matching is the single hottest theme: protamine→heparin, vitamin K/PCC→warfarin, idarucizumab→dabigatran, andexanet alfa→rivaroxaban/apixaban.
• Monitoring test for UFH = aPTT; for warfarin = INR; DOACs = none routinely — repeatedly asked as single-line recall.
• HIT management — switch to argatroban/fondaparinux; avoid warfarin until platelets recover.
• Warfarin-induced skin necrosis linked to protein C deficiency and the early procoagulant window.
• Vitamin K–dependent factors (II, VII, IX, X + protein C, S) and the factor VII shortest half-life fact.
• Anticoagulant of choice in pregnancy = LMWH/heparin; warfarin avoided (esp. 1st trimester).
• Mechanism specificity: fondaparinux = pure anti-Xa, dabigatran = direct thrombin, -xabans = direct Xa.
• DOAC renal dose adjustment and contraindication in mechanical valves (RE-ALIGN trial basis).

Rapid revision

1. Heparin works in vivo and in vitro; warfarin only in vivo.
2. Heparin activates ATIII; needs 18-saccharide chain to inhibit thrombin.
3. UFH → aPTT; LMWH/fondaparinux → anti-Xa (if any); warfarin → INR; DOACs → none.
4. Protamine reverses UFH fully, LMWH partially, fondaparinux not at all.
5. Vitamin K–dependent factors = II, VII, IX, X + proteins C & S (mnemonic 1972).
6. Factor VII has the shortest half-life → INR rises first; bridge warfarin with heparin.
7. Warfarin is teratogenic (fetal warfarin syndrome); use heparin/LMWH in pregnancy.
8. Warfarin reversal: vitamin K (slow) + PCC/FFP (immediate) for major bleed.
9. HIT (day 5–14, anti-PF4 IgG) → stop heparin, give argatroban/bivalirudin/fondaparinux; no platelets, no warfarin yet.
10. Dabigatran = thrombin inhibitor → idarucizumab; "-xabans" = Xa inhibitors → andexanet alfa.
11. DOACs are first-line in non-valvular AF, but warfarin stays for mechanical valves & APLA.
12. Target INR 2–3 (most indications), 2.5–3.5 for mechanical mitral valves.